Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL OF SYS6057 (RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (CHO CELLS)) OFFICIALLY INITIATED IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I clinical trial of SYS6057, a recombinant respiratory syncytial virus ("**RSV**") vaccine (Chinese Hamster Ovary ("**CHO**") cells) (the "**Product**") developed by the Group, has been officially initiated in China.

The Product is a recombinant RSV vaccine (CHO cells) developed by the Group, intended for the clinical prevention of lower respiratory tract disease caused by RSV infection. Its preclinical pharmacodynamics, pharmacokinetics and toxicology studies have been successfully completed. The study results indicated that the Product had good protective efficacy against challenge with both RSV A and B subtypes, exhibited high neutralising antibody activity, and demonstrated durable immune protection.

In July 2026, the Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China. Following the approval, the Group initiated a randomised, blinded, placebo-controlled Phase I clinical trial, aiming to evaluate the safety and immunogenicity of the Product administered to individuals aged 18 years and over. Currently, the recruitment and screening of participants for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.